Aloxiprin
Chemical compound
- B01AC15 (WHO) N02BA02 (WHO)
- aluminium 2-acetyloxybenzoate hydroxide
- 9014-67-9
- 3032790
- 2297682
Y
- 6QT214X4XU
- D07421 Y
- DTXSID80889395
- Interactive image
- Interactive image
- [Al+3].O=C(Oc1ccccc1C([O-])=O)C.[OH-].[O-]C(=O)c1ccccc1OC(=O)C
- CC(=O)Oc0ccccc0C(=O)O[Al](O)OC(=O)c1ccccc1OC(=O)C
InChI
- InChI=1S/2C9H8O4.Al.H2O/c2*1-6(10)13-8-5-3-2-4-7(8)9(11)12;;/h2*2-5H,1H3,(H,11,12);;1H2/q;;+3;/p-3Y
- Key:MANKSFVECICGLK-UHFFFAOYSA-KY
Aloxiprin (or aluminium acetylsalicylate) is a medical drug used for the treatment of pain and inflammation associated with muscular skeletal and joint disorders.[1] It is used for its properties as an anti-inflammatory, antipyretic and analgesic drug.[1] It is a chemical compound of aluminium hydroxide and aspirin.[2][3]
Alternative names and combinations
Contraindications
- People with allergies to salicylates.
- People with gastrointestinal ulcers.
- People with liver or kidney damage.
- Pregnant women in the 3rd trimester.
- Women who are breastfeeding.
- Use with other salicylates.
- Use with NSAIDs.
References
- ^ a b MIMS. "Aloxiprin". MIMS. Retrieved 16 April 2011.
- ^ Encarta. "Aloxiprin". Encarta. Retrieved 16 April 2011.[permanent dead link]
- ^ CUMMINGS AJ, MARTIN BK, WIGGINS LF (1963). "In vitro and in vivo properties of aloxiprin: a new aluminium derivative of acetylsalicylic acid". J. Pharm. Pharmacol. 15: 56–62. doi:10.1111/j.2042-7158.1963.tb12743.x. PMID 14024235. S2CID 33366977.
- ^ Geller J (1968). "A comparative trial of aloxiprin ('Palaprin Forte') and phenylbutazone ('Butazolidin')". The British Journal of Clinical Practice. 22 (9): 392–4. PMID 4876729.
- ^ Net Doctor UK. "Askit Powders". Treatments for joint, muscle and bone conditions. Retrieved 16 April 2011.
External links
- CTD's Aloxiprin page[permanent dead link] from the Comparative Toxicogenomics Database
- v
- t
- e
| Glycoprotein IIb/IIIa inhibitors |
|
|---|---|
| ADP receptor/P2Y12 inhibitors | |
| Prostaglandin analogue (PGI2) | |
| COX inhibitors | |
| Thromboxane inhibitors | |
| Phosphodiesterase inhibitors | |
| Other |
| Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
|---|---|---|---|---|---|
| Factor Xa inhibitors (with some II inhibition) |
| ||||
| Direct thrombin (IIa) inhibitors |
| ||||
| Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
| |
|---|---|
| pyrazolones / pyrazolidines | |
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams |
|
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
| |
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
